ARCHIVES

European Commission Approves Subcutaneous Rituximab

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Approves Gleevec For First Line Rx Of CML

January 31, 2003

In the Cancer Centers: Rosen Moves To City Of Hope

November 1, 2013

Strict System For Protection Of Human Subjects Ordered In Wake Of NIH Investigation

August 9, 1991

NCI To Slow New Center Development To Assure Funding For Existing Commitments, King Says

February 14, 1975

NCAB Jolted By 1977 Prelim Budget, “Outrageous” Prospect – Funding Only 30% Of Approved Grants

June 27, 1975

Phase III Five-Year Data Show Erbitux Increases Survival Of Head And Neck Cancer

September 26, 2008